The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016Cognitive Behavioral Therapy for Anxiety Disorders in Parkinson's Disease
Study Rationale:
Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life... -
MJFF Research Grant, 2009The Validation of Anxiety Scales in Parkinson's Disease
Objective/Rationale:
This study has two objectives:
1. To assess the occurrence and symptoms of anxiety disorders in Parkinson's disease, including atypical anxiety syndromes, and anxiety states... -
MJFF Research Grant, 2011Assessing and Diagnosing Anxiety in Patients with Parkinson's Disease
Promising Outcomes of Original Grant:
A previous MJFF sponsored study showed that the available anxiety questionnaires are not suitable to assess anxiety in Parkinson’s disease (PD). The different... -
Therapeutic Pipeline Program, 2015The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease
Study Rationale:
Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this... -
Research Grant, 2020Identification of Therapeutic Circuits to Address Anxiety and Depression Symptoms in Parkinson’s Disease
Study Rationale: Parkinson’s disease patients often experience depression and anxiety. Addressing these non-motor symptoms has not been the focus of Parkinson’s disease research though psychiatric...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease
Study Rationale: Genetic defects in the gene encoding alpha-synuclein cause the protein to aggregate in the brains of people with a familial form of Parkinson’s disease (PD). We have developed a novel...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.